This trial is evaluating whether Quality-of-Life Assessment will improve 2 primary outcomes, 3 secondary outcomes, and 1 other outcome in patients with Lung Cancer. Measurement will happen over the course of At 28 days.
This trial requires 74 total participants across 2 different treatment groups
This trial involves 2 different treatments. Quality-of-Life Assessment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
There are many treatment options for lung cancer patients. If the disease is managed by specialists like surgeons or radiation oncologists, treatment options are minimized and individualized with respect to age, disease stage, and patient health. If the disease is managed by general oncologists, clinicians must be vigilant about which medications can be used to optimize disease control, maximize symptom relief but minimize side effects.
Approximately 1 in 6 American adults are diagnosed with lung cancer each year. In California, it is estimated that 1 in 5 young adults and 1 in 7 middle-aged and elderly adults are diagnosed with lung cancer.
This article examines risk factors for cancer of the respiratory tract and for lung cancer in general. Several well-known factors have a significant role in the development or progression of lung cancer including smoking, radon exposure, asbestos, exposure to pesticides, family history, and other inherited or acquired genetic factors. In this article, the most important risk factors are asbestos exposure and tobacco use.
Although the most effective form of treatment for lung cancer remains surgery, with adjuvant radiotherapy, and with a 5-year survival rate approaching 50%, the prognosis is not favorable with a poorer prognosis and higher likelihood of dying before 5 years when lung cancer does metastasize.
The only significant early symptom of lung cancer is chest pain. Patients complain of coughing and shortness of breath, though they may also have weight loss, fever and night sweats. Persistent, chronic cough can only be explained by an underlying lung mass. Patients with loss of appetite but an otherwise unremarkable x ray are most likely to have either a brain tumour or metastasis.
Lung cancer is one of the leading causes of death in the US. It is a disease with several different types and is diagnosed with radiographic screenings such as computed tomography scans and chest X-rays. The cancer is staged, and if the cancer is found early, it can be treated with effective treatment. More research is needed on the causes and treatments of lung cancer.
To quantify quality of life in lung cancer patients, we have adapted the European Organization for the Study of Quality of Life questionnaire. Such an adaptation would be worthwhile also because we have demonstrated the close relationship between subjective health and other health variables. This type of questionnaire also allows us to use it in clinical trials because a similar instrument has already been used for some years
A statistically significant advantage in QoL and QoL of life was found when GCSI patients were treated compared to patients who received a placebo. Further studies are needed to investigate whether this difference can be translated into a larger clinical study with QoL measurement as one of the main objectives.
This initial study has shown that the DFSQ has the potential to be the next clinical tool to supplement QOL measures, e.g. performance status, used to measure the patients' global functional status.
A more general QOL assessment could lead to new discoveries of information on the natural course of cancer survivors' QOL. The question about the role of QOL has been the most frequently asked question. Quality-of-life research in the field of oncology has been mainly concerned with QOL assessment.
There have been some new discoveries for treating [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer). The first part of that is to discover what causes lung cancer in the first place? The second part is to find the best way to detect lung cancer earlier using the lowest number of tests so that more people can be treated. The third part is to treat the cancer.
For more information please visit us at Blk Super Specialties Hospital Delhi
To date, a majority of the existing epidemiological data is limited to small populations in Europe and North America. Findings from a recent study represents the largest investigation to date of all lung cancers in a genetically homogenous, well-characterized, and racially diverse population.